-
Report: Lannett could be first company bankrupted amid drug price scrutiny
LOS ANGELES — A new report from Citron Research is outlining why it expects Lannett to be the first pharmaceutical company to go bankrupt as a result of recent scrutiny on drug pricing. The analysis notes that Lannett is highly leveraged and dependent on three drugs for a bulk of its sales and that even modest price cuts to its biggest sellers would cause it to violate its debt covenants.New study: Growing share of drug prices go to rebates, supply chain
WASHINGTON — A new study from the Berkeley Research Group is taking a look at the share of prescription drug spending that’s retained by biopharmaceutical companies, generics makers, pharmacy benefit managers, health plans and other supply chain stakeholders.